Skip to main content

Table 4 Summary of the current knowledge on circulating miRNAs in the context of obesity and metabolic diseases

From: Role of microRNAs in obesity and obesity-related diseases

miRNA Process Reference
↓miR-126 T2D [148]
↑miR-1, miR-21, miR-133a, and miR-208 Myocardial infarction [150]
↑miR-122 Hepatic injury and steatosis [151]
↑let-7e Hypertension [152]
↑miR-130a and miR-195 Blood pressure [153]
miR-23a, miR-27a, miR-130, miR-195, miR-197, miR-320a, and miR-509-5p Metabolic syndrome [153, 154]
↑let-7g and miR-221 Female-specific in metabolic syndrome [155]
let-7b, miR-143, and miR-221 Atherogenic as and adipogenic processes [156]
↓miR-17-5p and miR-132 Obesity [157]
↓miR-122, miR-324-3p, miR-375, and miR-652; ↑miR-625 Pre-gestational and gestational obesity  
↑miR-140-5p, miR-142-3p, miR-222; ↓miR-532-5p, miR-125b, miR-130b, miR-221, miR-15a, miR-423-5p, and miR-520c-3p Morbidly obese patients [67]
↓miR-17-5p Coronary artery disease [205]
↑miR-33 Familial hypercholesterolemia and cardiometabolic disorders [206]
↑miR-122 NAFLD. Insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipid profile [207, 208]
↑miR-122 and miR-199a Children obesity [161]
↓miR-375 T1D onset [209]